TrialAnnals of oncology : official journal of the European Society for Medical Oncology2025

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.

L A Huppert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.